Inari Medical stock (US45332Y1092): earnings jump and new clot-treatment data keep focus on growth

Inari Medical has reported sharply higher quarterly revenue and narrowed losses, while presenting new clinical data for its minimally invasive clot-removal devices. The stock reacts to shifting expectations on growth and profitability.

Inari Medical reported strong first-quarter 2025 revenue growth and a smaller net loss, while also highlighting fresh clinical data for its minimally invasive clot-removal systems for venous thromboembolism. The company detailed the numbers in an earnings release on 05/06/2025, according to Inari Medical investor update as of 05/06/2025.

In that report for the quarter ended 03/31/2025, Inari Medical said revenue rose to 164.0 million USD, up around 25% year over year, while net loss narrowed to 6.3 million USD, according to Inari Medical investor update as of 05/06/2025. The company also pointed to continued adoption of its FlowTriever and ClotTriever systems for treating blood clots in the venous system.

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Inari Medical Inc
• Sector/industry: Medical devices / vascular intervention
• Headquarters/country: Irvine, California, United States
• Core markets: Treatment of venous thromboembolism and other vascular diseases
• Key revenue drivers: FlowTriever and ClotTriever thrombectomy systems, expanding procedure volumes
• Home exchange/listing venue: Nasdaq (ticker: NARI)
• Trading currency: USD

Inari Medical: core business model

Inari Medical focuses on developing catheter-based devices that allow physicians to remove blood clots from large veins without using thrombolytic drugs. The company positions its solutions as alternatives to systemic clot-dissolving therapies, which can carry a risk of serious bleeding complications in some patients.

The FlowTriever system is designed primarily for the treatment of pulmonary embolism, a condition where clots travel to the lungs and can impair circulation and oxygenation. Using a large-bore catheter, physicians can mechanically remove clots from the pulmonary arteries, seeking to rapidly improve hemodynamics and symptoms while avoiding thrombolytics.

The ClotTriever system targets deep vein thrombosis in the peripheral venous system, especially in the legs and pelvis. It uses a specialized catheter with a collection bag and expandable elements to remove organized clot from vessel walls in a single session, aiming to restore blood flow and potentially reduce the risk of long-term complications such as post-thrombotic syndrome.

Inari Medical’s business model is centered on selling single-use disposables and associated catheters to hospitals and clinics that perform minimally invasive vascular procedures. Revenue scales with the number of procedures performed, which in turn depends on physician adoption, hospital purchasing decisions, reimbursement frameworks and the strength of clinical evidence supporting the devices.

The company’s growth strategy includes expanding its dedicated sales force, educating physicians, publishing clinical data and securing broader reimbursement for its procedures. Inari Medical also invests heavily in research and development to refine its devices, explore new indications and develop additional technologies for venous and potentially arterial applications.

Main revenue and product drivers for Inari Medical

For Inari Medical, procedure volume growth remains the primary revenue driver. The company reported that first-quarter 2025 revenue of 164.0 million USD was largely driven by increased adoption of FlowTriever and ClotTriever devices across existing and new hospital accounts, according to Inari Medical investor update as of 05/06/2025.

Management highlighted that growth came from both deeper penetration in large, high-volume centers and expansion into community hospitals where minimally invasive clot removal is becoming more common. The company also indicated that international sales contributed a growing portion of total revenue, although the business remains primarily US-driven, according to Inari Medical investor update as of 05/06/2025.

Clinical evidence and guideline updates are important non-financial drivers for the stock, because they can influence how frequently physicians choose mechanical thrombectomy over drug-based therapies. In 2024 and early 2025, Inari Medical presented additional data from registries and studies evaluating the safety and effectiveness of FlowTriever and ClotTriever systems, including real-world outcomes in pulmonary embolism and deep vein thrombosis patients, as referenced in company conference presentations cited in its 2024 annual report published on 02/26/2025.

Profitability remains a key focus area. In the first quarter of 2025, gross margin stayed at a high level, while operating expenses rose due to investment in sales infrastructure, clinical research and product development, leading to a reduced but still negative operating result, according to Inari Medical investor update as of 05/06/2025. Investors often monitor whether revenue growth will eventually outpace spending and drive sustainable operating profits.

Beyond its two flagship products, Inari Medical is working on platform extensions and new devices aimed at chronic venous disease and other vascular conditions. While these pipeline products currently contribute little to revenue, the company has indicated that it views them as important long-term growth engines, referencing development programs outlined in its 2024 Form 10-K filed with the SEC on 02/26/2025.

Why Inari Medical matters for US investors

Inari Medical is listed on Nasdaq under the ticker NARI and operates in the US medical-device sector, which is closely followed by American investors seeking exposure to healthcare innovation. Its core focus on venous thromboembolism addresses a major clinical need in US hospitals, where pulmonary embolism and deep vein thrombosis remain significant causes of morbidity and mortality.

US payers and hospital systems are increasingly focused on both clinical outcomes and cost efficiency. Devices that can shorten hospital stays, reduce complications and avoid intensive care or systemic thrombolytics may attract interest from administrators and insurers. Inari Medical’s outcomes data and economic analyses, as referenced in conference materials summarized in its 2024 annual report published on 02/26/2025, are therefore important for understanding its long-term role in US healthcare delivery.

For US-based portfolios, Inari Medical may be seen as a pure-play bet on minimally invasive vascular interventions, in contrast to diversified medtech conglomerates that span multiple therapeutic areas. This concentration can translate into higher growth potential but also higher sensitivity to competition, reimbursement decisions and regulatory developments affecting venous thrombectomy.

Risks and open questions

Despite its rapid revenue growth, Inari Medical continues to post net losses, mainly due to substantial spending on sales, marketing and research. The key question for many market participants is whether management can balance investment in growth with a path toward sustainable profitability without sacrificing product innovation.

Another risk factor is competitive pressure. Larger medical-device companies and emerging startups are also targeting mechanical thrombectomy and related vascular indications, which could affect pricing power and hospital purchasing decisions over time. In its 2024 Form 10-K filed on 02/26/2025, Inari Medical noted the presence of current and potential competitors with greater financial and commercial resources.

Regulatory and reimbursement frameworks also remain important variables. Changes in US Medicare or private-insurance policies regarding thrombectomy procedures, as well as evolving clinical guidelines, could influence procedure volumes. The company has acknowledged in regulatory filings that unfavorable reimbursement changes represent a material risk to its business model.

Conclusion

Inari Medical has combined strong top-line growth with a still-loss-making but improving bottom line, supported by rising adoption of its clot-removal devices and a growing body of clinical data. The first-quarter 2025 results for the period ended 03/31/2025 showed revenue expansion, high gross margins and ongoing investment in commercialization and R&D, according to Inari Medical investor update as of 05/06/2025. For investors in the US and abroad, the stock’s appeal is tied to its exposure to minimally invasive vascular care, but it also carries execution, competition and reimbursement risks that warrant close monitoring over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.